JP2013522618A5 - - Google Patents

Info

Publication number

JP2013522618A5

JP2013522618A5 JP2012557648A JP2012557648A JP2013522618A5 JP 2013522618 A5 JP2013522618 A5 JP 2013522618A5 JP 2012557648 A JP2012557648 A JP 2012557648A JP 2012557648 A JP2012557648 A JP 2012557648A JP 2013522618 A5 JP2013522618 A5 JP 2013522618A5

Authority

JP

Japan

Prior art keywords

procalcitonin

concentration

urine

aliquots

urinary tract

Prior art date

2011-03-15

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 108010048233 Procalcitonin Proteins 0.000 claims 17
• CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims 17
• 210000002700 urine Anatomy 0.000 claims 11
• 238000000034 method Methods 0.000 claims 10
• MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical compound C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 claims 8
• HQCYVSPJIOJEGA-UHFFFAOYSA-N methoxycoumarin Chemical compound C1=CC=C2OC(=O)C(OC)=CC2=C1 HQCYVSPJIOJEGA-UHFFFAOYSA-N 0.000 claims 8
• 208000019206 urinary tract infection Diseases 0.000 claims 7
• QWZHDKGQKYEBKK-UHFFFAOYSA-N 3-aminochromen-2-one Chemical compound C1=CC=C2OC(=O)C(N)=CC2=C1 QWZHDKGQKYEBKK-UHFFFAOYSA-N 0.000 claims 4
• 229910052693 Europium Inorganic materials 0.000 claims 4
• 229910052772 Samarium Inorganic materials 0.000 claims 4
• 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 4
• OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims 4
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 4
• KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 claims 4
• 239000003153 chemical reaction reagent Substances 0.000 claims 3
• 150000001875 compounds Chemical class 0.000 claims 3
• 208000008035 Back Pain Diseases 0.000 claims 2
• 206010021113 Hypothermia Diseases 0.000 claims 2
• 208000008930 Low Back Pain Diseases 0.000 claims 2
• 206010037660 Pyrexia Diseases 0.000 claims 2
• 206010062910 Vascular infections Diseases 0.000 claims 2
• 238000003745 diagnosis Methods 0.000 claims 2
• 230000002631 hypothermal effect Effects 0.000 claims 2
• 206010024378 leukocytosis Diseases 0.000 claims 2
• 201000002364 leukopenia Diseases 0.000 claims 2
• 231100001022 leukopenia Toxicity 0.000 claims 2
• 238000012544 monitoring process Methods 0.000 claims 2
• 239000013641 positive control Substances 0.000 claims 2
• 230000000306 recurrent effect Effects 0.000 claims 2
• 208000024891 symptom Diseases 0.000 claims 2
• 208000011580 syndromic disease Diseases 0.000 claims 2
• 230000002485 urinary effect Effects 0.000 claims 2
• 239000007853 buffer solution Substances 0.000 claims 1
• 239000007850 fluorescent dye Substances 0.000 claims 1
• 238000000338 in vitro Methods 0.000 claims 1
• 208000015181 infectious disease Diseases 0.000 claims 1
• 239000013642 negative control Substances 0.000 claims 1
• 239000000243 solution Substances 0.000 claims 1